Setting the Benchmark for Precision and Credibility in Botanical Drug Development
Canurta proudly introduces a transformative development in hemp extract analysis. In a significant advancement for the field of botanical drug development, Canurta, in collaboration with Applied Pharmaceutical Innovation (API), has unveiled a validated method for the detection of cannflavins in hemp extracts that exceeds the global benchmarks set by the ICH and EMA.
Central to this breakthrough is an advanced Liquid Chromatography Mass Spectrometry (LC-MS) assay that accurately identifies cannflavins A, B, and C within hemp extract samples, showcasing an exceptional level of precision. Notably, the incorporation of the deuterated analog, cannabidiol-D3, as an internal standard, further solidifies the reliability of the results produced.
Among the standout features of this assay are its impressive linearity and sensitivity. It boasts a lower limit of quantification of 0.5 μg/mL and an exceptional limit of detection reaching 0.25 μg/mL. Testament to its robustness, Canurta has applied this method to gauge cannflavin release in innovative topical formulations.
"The introduction of this method is emblematic of Canurta's dedication to spearheading innovation," said Akeem Gardner, Founder & CEO of Canurta. "We remain steadfast in our mission to elevate the standards of hemp extract analysis and to continually shape a future grounded in excellence and reliability."
Researchers, scholars, and industry experts are invited to read the full details of this development in the comprehensive research paper available now:
This announcement underscores just the beginning of a series of innovations Canurta envisions. The industry can anticipate many more groundbreaking contributions in the near future.
For further inquiries or additional information, please contact: hello@canurta.com
Comments